Re:Pair Genomics
Re:Pair Genomics is a biotechnology company focused on accelerating gene therapy research through AI-powered design of regulatory elements. Their machine-learning algorithm designs promoters and enhancers within a day, offering customized solutions for researchers targeting specific cell types or transfecting cells with DNA plasmids. This approach reduces off-targeting effects, optimizes DNA plasmid size, increases transfection efficiency, reduces toxicity, and controls gene expression timing. The company emphasizes speed, accuracy, and flexibility in its algorithm, which screens databases to identify optimal DNA sequences. Re:Pair Genomics aims to streamline the design process, moving from months of traditional testing to a one-day custom design. They have achieved recognition as a finalist in several business plan competitions and pitch events, including TEMRIS America Business Plan Competition, Hatchery NEST pitch competition, and Johnson & Johnson Innovation’s Cell & Gene Therapy QuickPitch Poster Session, and have won competitions like Pitch Perfect and Build-a-Biotech-Venture. They also secured grants from Mitacs Accelerate and Intellectual Property Ontario (IPON), and have been featured by TechAlliance as an i.d.e.a. Fund recipient.
Re:Pair Genomics
Re:Pair Genomics is a biotechnology company focused on accelerating gene therapy research through AI-powered design of regulatory elements. Their machine-learning algorithm designs promoters and enhancers within a day, offering customized solutions for researchers targeting specific cell types or transfecting cells with DNA plasmids. This approach reduces off-targeting effects, optimizes DNA plasmid size, increases transfection efficiency, reduces toxicity, and controls gene expression timing. The company emphasizes speed, accuracy, and flexibility in its algorithm, which screens databases to identify optimal DNA sequences. Re:Pair Genomics aims to streamline the design process, moving from months of traditional testing to a one-day custom design. They have achieved recognition as a finalist in several business plan competitions and pitch events, including TEMRIS America Business Plan Competition, Hatchery NEST pitch competition, and Johnson & Johnson Innovation’s Cell & Gene Therapy QuickPitch Poster Session, and have won competitions like Pitch Perfect and Build-a-Biotech-Venture. They also secured grants from Mitacs Accelerate and Intellectual Property Ontario (IPON), and have been featured by TechAlliance as an i.d.e.a. Fund recipient.